These findings support the use of early BCR::ABL1 kinetics to guide treatment reassessment; in particular, children with poor early molecular responses should be considered for finding the cause and may switch to a second-generation TKI, in accordance with current pediatric CML recommendations. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.